drugset / Trial / NCT04947631
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multi-center, randomized, double-blinded, double-dummy, parallel group, 48-week study to evaluated the efficacy and safety of DKF-313 (dutasteride and tadalafil) in patients with benign prostatic hyperplasia.
Timeline
- Start
- 2021-07-27
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dutasteride | Small molecule | 0.5 mg | — |
| Comparator | Tadalafil | Small molecule | 5 mg | — |